We are excited to announce that Biocytogen will exhibit at the 17th Annual World Bispecific Summit September 15th–17th in Boston, MA. As one of the leading events dedicated to bispecific and multispecific antibody development, the summit is an excellent opportunity to connect with industry experts and explore the latest innovations in antibody engineering. Visit our team at booth # to learn how Biocytogen's fully human antibody discovery platforms and humanized mouse models accelerate therapeutic development.
What is the 17th World Bispecific Summit?
The World Bispecific Summit is a premier conference dedicated to advancing the discovery, engineering, and clinical development of bispecific and multispecific antibodies. The event brings together scientists, researchers, and biotechnology leaders to explore innovative molecular designs, AI-guided drug discovery, and other next-generation approaches that are shaping the future of antibody therapeutics. With keynote presentations, scientific sessions, poster presentations, and networking opportunities, attendees can discover the latest technologies, exchange ideas, and build collaborations that drive the future of therapies.
Event Overview
Date: September 15th - 17th, 2026
Venue: The Westin Boston Seaport District, 425 Summer St, Boston, MA 02210
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
